The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
May. 21, 2024

Filed:

Feb. 09, 2023
Applicant:

Immatics Biotechnologies Gmbh, Tuebingen, DE;

Inventors:

Toni Weinschenk, Tuebingen, DE;

Oliver Schoor, Tuebingen, DE;

Claudia Trautwein, Tuebingen, DE;

Norbert Hilf, Tuebingen, DE;

Steffen Walter, Tuebingen, DE;

Harpreet Singh, Tuebingen, DE;

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
C07K 7/06 (2006.01); A61K 35/17 (2015.01); A61K 39/00 (2006.01); C07K 7/08 (2006.01); C07K 14/47 (2006.01); C07K 14/495 (2006.01); C07K 14/725 (2006.01); C07K 16/40 (2006.01); C07K 19/00 (2006.01); C12N 5/0783 (2010.01); C12N 9/02 (2006.01); C12N 9/10 (2006.01); A61K 38/00 (2006.01);
U.S. Cl.
CPC ...
A61K 35/17 (2013.01); A61K 39/0011 (2013.01); C07K 7/06 (2013.01); C07K 7/08 (2013.01); C07K 14/47 (2013.01); C07K 14/4748 (2013.01); C07K 14/495 (2013.01); C07K 14/7051 (2013.01); C07K 16/40 (2013.01); C07K 19/00 (2013.01); C12N 5/0638 (2013.01); C12N 9/0036 (2013.01); C12N 9/13 (2013.01); A61K 38/00 (2013.01); A61K 2039/5158 (2013.01); A61K 2039/572 (2013.01); C07K 2317/34 (2013.01); C07K 2319/00 (2013.01); C12N 2502/1157 (2013.01); C12Y 208/02011 (2013.01);
Abstract

The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to 11 novel peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.


Find Patent Forward Citations

Loading…